Golden Biotechnology Corporation

Equities

4132

TW0004132006

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
25.1 ^TWD	-1.76%		+13.83%	-36.05%

29/04	Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/01	Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol	CI

Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019

August 07, 2019 at 12:02 am IST

Golden Biotechnology Corporation announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was TWD 31.789 million compared to TWD 44.718 million a year ago. Operating loss was TWD 154.015 million compared to TWD 163.660 million a year ago. Net loss was TWD 159.676 million compared to TWD 166.953 million a year ago. Basic loss per share was TWD 1.4 compared to TWD 1.49 a year ago.

Latest news about Golden Biotechnology Corporation

Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol	18/01	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer	05/23/05	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	12/22/12	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	28/22/28	CI
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients	07/22/07	CI
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients	16/21/16	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	16/21/16	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries	04/21/04	CI
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia	26/20/26	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020	12/20/12	CI
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA	01/20/01	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	06/20/06	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	07/19/07	CI
Golden Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	02/19/02	CI
Golden Biotechnology Corporation(GTSM:4132) added to S&P Global BMI Index	24/18/24	CI
Golden Biotechnology Corporation announced that it has received TWD 48 million in funding	25/18/25	CI
Golden Biotechnology Corporation announced a financing transaction	20/18/20	CI
Golden Biotechnology Corp. announced that it expects to receive TWD 18.9 million in funding	23/16/23	CI
Golden Biotechnology Corp. cancelled the transaction announced on December 22, 2015	12/16/12	CI
Golden Biotechnology Corp. announced that it expects to receive TWD 380 million in funding	12/16/12	CI
Golden Biotechnology Corp. announced that it has received TWD 32.6 million in funding.	18/16/18	CI

Chart Golden Biotechnology Corporation

Duration

Period

More charts

Company Profile

Golden Biotechnology Corp is a Taiwan-based company mainly engaged in the development of new anti-cancer drugs. The Company's main development projects are novel compounds of Antroquinonol for the treatment of non-small cell lung cancer, acute myeloid leukemia, pancreatic cancer, hyperlipidemia, hepatitis B, and Corona Virus Disease 2019 (Covid-19), which are broadly effective small molecule drugs with no systemic toxicity. The Company is also engaged in the manufacture and sales of health foods and dietary supplements. The main products include antrodia camphorata mycelium capsules and others. The Company sells products in the Taiwan market as well as in other areas of Asia.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GOLDEN BIOTECHNOLOGY CORPORATION	-36.05%	11Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.65TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.62TCr
BEIGENE, LTD.	-20.90%	1.54TCr
WUXI APPTEC CO., LTD.	-46.14%	1.52TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.35TCr

Bio Therapeutic Drugs